Title

Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis
A Randomized, Double-blind, Placebo Controlled, Parallel Group Trial of Cyclamen Europaeum Extract Nasal Spray 10% (v/v) in the Treatment of Subjects With Acute Sinusitis
  • Phase

    N/A
  • Lead Sponsor

    Dey
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    48
To evaluate the efficacy and safety of Cyclamen europaeum extract 10 % (v/v) compared to placebo in subjects with acute sinusitis
Study Started
Nov 30
2007
Primary Completion
Sep 30
2008
Study Completion
Dec 31
2009
Last Update
Jun 04
2013
Estimate

Drug Cyclamen Europaeum

Nasal spray 10% (V/V),one spray per nostril daily for 7 days.

Cyclamen Europaeum Experimental

Placebo Placebo Comparator

Criteria

Inclusion Criteria:

Adults age 18-70
Must be symptomatic on the basis of subject assessments of total sympton score.
Evidence of mucopurulence on nasal endoscopy
Evidence of inflammation upon nasal endoscopy
CT scan with radiographic signs of acute sinusitis
Able to complete all study activities or procedures through the end of the study, including all visits and tests, and capable of selfadministration of study medication
Agree to abide by the study protocol and its restrictions

Exclusion Criteria:

Known history of hypogammaglobulinemia, immotile cilia syndrome, atrophic rhinitis, rhinitis medicamentosa, or cystic fibrosis
Known hypersensitivity to Cyclamen, Primula, or other Primulaceae
Serious unstable comorbidity such as malignancy (other than squamous or basal cell carcinoma of the skin) or sever renal or hepatic disease.
Abnormal screening laboratory/imaging test results
Condition(s) that compromise the ability to either administer the agent or assess the risks/benefits (eg mucocele, choanal polyp, Stage 4 polyposis or cyst extending below the inferior turbinate, deviated septum, facial trauma, or birth defect)
Expansile mass or bony erosion on sinus radiograph
Females who are pregnant, planning to become pregnant or currently breastfeeding.
History of viral upper respiratory infection (URI) in the past 2 weeks
Temperature greater than 102.5°F
Facial or periorbital edema
Local complications including orbital cellulitis; acute abnormalities of extraocular movements; cavernous vein thrombosis; dental or facial abscess
Altered mental status
Recent nasal or sinus surgery (within 3 months or less) or planned surgery within the next 3 months
Use of intranasal antibiotics within the previous 30 days or systemic antibiotics within the previous 15 days
Use of oral and/or topical nasal decongestants within the previous 7 days
Had radiation therapy or chemotherapy within the previous 12 months
Have used an investigational drug or device within 30 days prior to screening
Have a history of illegal drug or alcohol abuse within the past 5 years
Have major unstable organ system disease that could place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives Subjects who have asthma, seasonal and/or perennial allergic rhinitis will be allowed to enter the study.
No Results Posted